Literature DB >> 1827161

Immunologic effects of plasmapheresis synchronized with pulse cyclophosphamide in systemic lupus erythematosus.

P C Dau1, J Callahan, R Parker, J Golbus.   

Abstract

Extensive immunologic evaluation was made of a patient with severe systemic lupus erythematosus (SLE) undergoing 6 cycles of plasmapheresis combined with pulsed cyclophosphamide therapy. Clinical remission ensued accompanied by normalization of levels of circulating autoantibodies, immune complexes, complement proteins, interleukin 2 (IL-2) and IL-2 receptor. High spontaneous peripheral blood lymphocyte proliferation fluctuated widely with plasmapheresis, but was consistently reduced after cyclophosphamide. Circulating B cells fell by 85% and remained low at one year, despite recovery of the serum IgG level. Circulating T cells declined by 48%, chiefly in the immunologically naive CD4+CD45R+ T cell subset. This was associated with the emergence of a CD8+DR+CDw29+ T cell subset signifying immunologically mature, activated cytotoxic/suppressive T cells, which might have served to control the autoreactive B and T cell populations. Pulsed cyclophosphamide synchronized with plasmapheresis profoundly affected the immune system of our patient. The association of these immunological changes with clinical recovery warrants further investigation of this new therapeutic approach in SLE.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1827161

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  5 in total

1.  Effect of plasmapheresis on ligand binding capacity and expression of erythrocyte complement receptor type 1 (CR1) of patients with systemic lupus erythematosus (SLE).

Authors:  I Csípö; E Kiss; P Soltész; P Antal-Szalmás; G Szegedi; J H Cohen; R P Taylor; M Kávai
Journal:  Clin Exp Immunol       Date:  1999-12       Impact factor: 4.330

2.  The favourable effect of cyclophosphamide pulse therapy in the treatment of massive pulmonary haemorrhage in systemic lupus erythematosus.

Authors:  M Fukuda; Y Kamiyama; K Kawahara; K Kawamura; T Mori; M Honda
Journal:  Eur J Pediatr       Date:  1994-03       Impact factor: 3.183

Review 3.  Lupus nephritis in childhood and adolescence.

Authors:  J S Cameron
Journal:  Pediatr Nephrol       Date:  1994-04       Impact factor: 3.714

Review 4.  Therapeutic apheresis in autoimmune diseases.

Authors:  Rolf Bambauer; Reinhard Latza; Carolin Bambauer; Daniel Burgard; Ralf Schiel
Journal:  Open Access Rheumatol       Date:  2013-11-13

Review 5.  Immunosuppressive agents for dermatological indications in the ongoing COVID-19 pandemic: Rationalizing use and clinical applicability.

Authors:  Ananta Khurana; Snigdha Saxena
Journal:  Dermatol Ther       Date:  2020-06-23       Impact factor: 3.858

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.